Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study ...

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically ...

The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported. Active surveillance (AS) should be cautiously offered to men ...

Adding external-beam radiation to brachytherapy does not improve 5-year freedom from progression (FFP) for men with intermediate-risk prostate cancer, but it does increase treatment toxicity. The ...

SBRT is noninferior to traditional radiation for low- to intermediate-risk localized prostate cancer, offering a viable treatment alternative. The PACE-B study showed a 95.8% five-year rate of no ...

The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...

Researchers have characterized prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

SAN ANTONIO, October 22, 2018 -- Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, ...